Biotech | April 04, 2025
Wacker collaborates with RNAV8 Bio to enhance mRNA therapeutics development
This collaboration positions WACKER and RNAV8 as premium mRNA service providers
This collaboration positions WACKER and RNAV8 as premium mRNA service providers
Approval based on AEGEAN Phase III trial results which showed a 32% reduction in the risk of recurrence, progression or death vs. neoadjuvant chemotherapy alone
Approval brings AstraZeneca and Daiichi Sankyo’s Enhertu earlier in the treatment of HR-positive, HER2-low breast cancer and broadens the eligible patient population to those with HER2-ultralow disease
The company expects to launch this product through its marketing partner in the near future
The IND application supports the next phase of development of SBO-154
New trontinemab data continue to support rapid and deep, dose-dependent reduction of amyloid plaques in Phase Ib/IIa Brainshuttle AD study
Awards highlight Avantor's commitment to the Biopharma industry
Pantoprazole Sodium for Injection, 40 mg/vial (Single-Dose Vial) have an estimated market size of US$ 48 million for twelve months ending December 2024 according to IQVIA
Being a premium partner for pharmaceutical companies by contributing to safety and productivity of pharmaceutical manufacture
The company offers customized formulations tailored to align with each brand’s identity and consumer needs
Subscribe To Our Newsletter & Stay Updated
